398 related articles for article (PubMed ID: 29174942)
1. Comparative Effectiveness of Initial Surgery vs Initial Systemic Therapy for Metastatic Kidney Cancer in the Targeted Therapy Era: Analysis of a Population-based Cohort.
Macleod LC; Odisho AY; Tykodi SS; Holt SK; Harper JD; Gore JL
Urology; 2018 Mar; 113():146-152. PubMed ID: 29174942
[TBL] [Abstract][Full Text] [Related]
2. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
3. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience.
Choi CI; Kang M; Sung HH; Jeon HG; Jeong BC; Jeon SS; Lee HM; Seo SIL
Clin Genitourin Cancer; 2018 Dec; 16(6):e1189-e1199. PubMed ID: 30262447
[TBL] [Abstract][Full Text] [Related]
4. Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry.
de Groot S; Redekop WK; Sleijfer S; Oosterwijk E; Bex A; Kiemeney LA; Uyl-de Groot CA
Urology; 2016 Sep; 95():121-7. PubMed ID: 27179773
[TBL] [Abstract][Full Text] [Related]
5. Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting.
Klatte T; Fife K; Welsh SJ; Sachdeva M; Armitage JN; 'Aho T; Riddick AC; Matakidou A; Eisen T; Stewart GD
World J Urol; 2018 Mar; 36(3):417-425. PubMed ID: 29256020
[TBL] [Abstract][Full Text] [Related]
6. Cytoreductive nephrectomy with thrombectomy before targeted therapy improves survival for metastatic renal cell carcinoma with venous tumor thrombus: a single-center experience.
Qi N; Wu P; Chen J; Li T; Ning X; Wang J; Gong K
World J Surg Oncol; 2017 Jan; 15(1):4. PubMed ID: 28056988
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.
Bex A; Mulders P; Jewett M; Wagstaff J; van Thienen JV; Blank CU; van Velthoven R; Del Pilar Laguna M; Wood L; van Melick HHE; Aarts MJ; Lattouf JB; Powles T; de Jong Md PhD IJ; Rottey S; Tombal B; Marreaud S; Collette S; Collette L; Haanen J
JAMA Oncol; 2019 Feb; 5(2):164-170. PubMed ID: 30543350
[TBL] [Abstract][Full Text] [Related]
8. Overall survival in patients with metastatic renal cell carcinoma and clinical N1 disease undergoing cytoreductive nephrectomy and lymph node dissection.
Faiena I; Salmasi A; Lenis AT; Donin NM; Johnson DC; Bachour K; Drakaki A; Belldegrun AS; Pantuck AJ; Chamie K
Urol Oncol; 2018 Feb; 36(2):79.e19-79.e26. PubMed ID: 29103965
[TBL] [Abstract][Full Text] [Related]
9. Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma.
Day D; Kanjanapan Y; Kwan E; Yip D; Lawrentschuk N; Davis ID; Azad AA; Wong S; Rosenthal M; Gibbs P; Tran B
Intern Med J; 2016 Nov; 46(11):1291-1297. PubMed ID: 27507629
[TBL] [Abstract][Full Text] [Related]
10. Assessment of survival of patients with metastatic clear cell renal cell carcinoma after radical cytoreductive nephrectomy versus no surgery: a seer analysis.
Xiao WJ; Zhu Y; Dai B; Zhang HL; Ye DW
Int Braz J Urol; 2015; 41(2):288-95. PubMed ID: 26005970
[TBL] [Abstract][Full Text] [Related]
11. The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapies.
Claeys T; Lumen N; Kumps C; Praet M; De Meerleer G; Rottey S; Ost P; Devisschere P; Villeirs G; Fonteyne V; Decaestecker K
Urol Oncol; 2017 Apr; 35(4):152.e13-152.e22. PubMed ID: 28153420
[TBL] [Abstract][Full Text] [Related]
12. Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study.
Hanna N; Sun M; Meyer CP; Nguyen PL; Pal SK; Chang SL; de Velasco G; Trinh QD; Choueiri TK
J Clin Oncol; 2016 Sep; 34(27):3267-75. PubMed ID: 27325852
[TBL] [Abstract][Full Text] [Related]
13. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A
Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042
[TBL] [Abstract][Full Text] [Related]
14. Normalization of C-reactive protein levels following cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors is associated with improved overall survival.
Teishima J; Ohara S; Shinmei S; Inoue S; Hayashi T; Mochizuki H; Mita K; Shigeta M; Matsubara A
Urol Oncol; 2018 Jul; 36(7):339.e9-339.e15. PubMed ID: 29773493
[TBL] [Abstract][Full Text] [Related]
15. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features.
Mathieu R; Pignot G; Ingles A; Crepel M; Bigot P; Bernhard JC; Joly F; Guy L; Ravaud A; Azzouzi AR; Gravis G; Chevreau C; Zini L; Lang H; Pfister C; Lechevallier E; Fais PO; Berger J; Vayleux B; Roupret M; Audenet F; Descazeaud A; Rigaud J; Machiels JP; Staehler M; Salomon L; Ferriere JM; Kleinclauss F; Bensalah K; Patard JJ
Urol Oncol; 2015 Aug; 33(8):339.e9-15. PubMed ID: 26087971
[TBL] [Abstract][Full Text] [Related]
16. The Association Between Cytoreductive Nephrectomy and Overall Survival in Metastatic Renal Cell Carcinoma with Primary Tumor Size ≤4 cm.
Tappero S; Barletta F; Piccinelli ML; Cano Garcia C; Incesu RB; Morra S; Scheipner L; Tian Z; Parodi S; Dell'Oglio P; Palumbo C; Briganti A; De Cobelli O; Chun FKH; Graefen M; Longo N; Ahyai S; Saad F; Shariat SF; Suardi N; Borghesi M; Terrone C; Karakiewicz PI
Eur Urol Focus; 2023 Sep; 9(5):742-750. PubMed ID: 36906483
[TBL] [Abstract][Full Text] [Related]
17. Population-based analysis of factors associated with survival in patients undergoing cytoreductive nephrectomy in the targeted therapy era.
Culp SH; Karam JA; Wood CG
Urol Oncol; 2014 Jul; 32(5):561-8. PubMed ID: 24709415
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: A Systematic Review With a Meta-Analysis.
Petrelli F; Coinu A; Vavassori I; Cabiddu M; Borgonovo K; Ghilardi M; Lonati V; Barni S
Clin Genitourin Cancer; 2016 Dec; 14(6):465-472. PubMed ID: 27138461
[TBL] [Abstract][Full Text] [Related]
19. Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era.
Abern MR; Scosyrev E; Tsivian M; Messing EM; Polascik TJ; Dudek AZ
Anticancer Res; 2014 May; 34(5):2405-11. PubMed ID: 24778051
[TBL] [Abstract][Full Text] [Related]
20. Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma.
Bhindi B; Habermann EB; Mason RJ; Costello BA; Pagliaro LC; Thompson RH; Leibovich BC; Boorjian SA
J Urol; 2018 Sep; 200(3):528-534. PubMed ID: 29574109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
